You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海正藥業(600267.SH):孫公司與再鼎簽署“甲苯磺酸奧瑪環素”注射劑和口服片劑的獨家推廣協議
格隆匯 03-20 16:58

格隆匯3月20日丨海正藥業(600267.SH)公佈,公司第八屆董事會第十次會議召開,審議通過關於孫公司輝正(上海)醫藥科技有限公司與再鼎醫藥(上海)有限公司簽署產品獨家推廣協議的議案;

同意孫公司輝正與再鼎醫藥(上海)有限公司(“再鼎”)簽署全球創新藥“甲苯磺酸奧瑪環素”(Omadacycline,“奧瑪環素”)注射劑和口服片劑的《獨家推廣協議》。

再鼎指定輝正在推廣服務區域(中國,但不包括香港特別行政區、澳門特別行政區和台灣地區)對奧瑪環素注射劑和口服片劑進行獨家推廣服務。

作為再鼎根據本協議授予輝正權利的部分對價,輝正應向再鼎支付人民幣2.3億元的不可抵扣的預付款(“預付款”)。該預付款應由輝正按下述期限分批支付給再鼎:

1)生效日期後30日內,輝正應向再鼎支付人民幣9000萬元;

2)在再鼎獲得該產品在獲得國家藥品監督管理局新藥上市批准後60日內,輝正應向再鼎支付人民幣7000萬元;

3)產品通過《國家醫保目錄》(NRDL)談判並被《國家醫保目錄》收錄後的60日內,輝正應向再鼎支付人民幣7000萬元。

若發生奧瑪環素未能按約定獲批的情形,雙方同意在總額不超過2.3億元的範圍內調整相關預付款。

銷售里程碑付款:從產品在授權區域啟動商業銷售開始,將根據實際年淨銷售額向再鼎支付里程碑費用,該項費用累計最高不超過相當於4050萬美元的人民幣金額。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account